Editorial: HIV and Cancer Immunotherapy: Similar Challenges and Converging Approaches.
作者信息
Paiardini Mirko, Dhodapkar Kavita, Harper Justin, Deeks Steven G, Ahmed Rafi
机构信息
Division of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, GA, United States.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, United States.
出版信息
Front Immunol. 2020 Mar 31;11:519. doi: 10.3389/fimmu.2020.00519. eCollection 2020.
Abstract
摘要
相似文献
1
Editorial: HIV and Cancer Immunotherapy: Similar Challenges and Converging Approaches.社论：HIV与癌症免疫疗法：相似的挑战与趋同的方法
Front Immunol. 2020 Mar 31;11:519. doi: 10.3389/fimmu.2020.00519. eCollection 2020.
2
Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.基于过继性细胞疗法和免疫检查点阻断疗法的实体瘤个性化联合免疫疗法的前景。
Nihon Rinsho Meneki Gakkai Kaishi. 2017;40(1):68-77. doi: 10.2177/jsci.40.68.
3
HIV immunotherapy comes of age: implications for prevention, treatment and cure.HIV免疫疗法走向成熟：对预防、治疗和治愈的影响。
Expert Rev Clin Immunol. 2016;12(2):91-4. doi: 10.1586/1744666X.2016.1112269. Epub 2015 Dec 2.
4
Cancer immunotherapy: harnessing the immune system to battle cancer.癌症免疫疗法：利用免疫系统对抗癌症。
J Clin Invest. 2015 Sep;125(9):3335-7. doi: 10.1172/JCI83871. Epub 2015 Sep 1.
5
An unexpected journey: how cancer immunotherapy has paved the way for an HIV-1 cure.一段意外之旅：癌症免疫疗法如何为治愈HIV-1铺平道路。
Discov Med. 2015 Mar;19(104):229-38.
6
[Era of cancer immunotherapy has come].癌症免疫治疗时代已经来临。
Nihon Rinsho Meneki Gakkai Kaishi. 2016;39(3):164-71. doi: 10.2177/jsci.39.164.
7
Editorial: Combinatorial Approaches to Enhance Anti-tumor Immunity: Focus on Immune Checkpoint Blockade Therapy.社论：增强抗肿瘤免疫的联合方法：聚焦免疫检查点阻断疗法
Front Immunol. 2019 Sep 6;10:2083. doi: 10.3389/fimmu.2019.02083. eCollection 2019.
8
The Use of the Humanized Mouse Model in Gene Therapy and Immunotherapy for HIV and Cancer.人源化小鼠模型在 HIV 和癌症的基因治疗和免疫治疗中的应用。
Front Immunol. 2018 Apr 20;9:746. doi: 10.3389/fimmu.2018.00746. eCollection 2018.
9
New challenges in therapeutic vaccines against HIV infection.针对HIV感染的治疗性疫苗面临的新挑战。
Expert Rev Vaccines. 2017 Jun;16(6):587-600. doi: 10.1080/14760584.2017.1322513. Epub 2017 May 4.
10
Rationale for an Association Between PD1 Checkpoint Inhibition and Therapeutic Vaccination Against HIV.PD1 检查点抑制与抗 HIV 治疗性疫苗之间关联的理由。
Front Immunol. 2018 Oct 23;9:2447. doi: 10.3389/fimmu.2018.02447. eCollection 2018.
引用本文的文献
1
Pediatric Oncology, Palliative Care and Low- or Middle- Income Countries: A Call for Action.儿科肿瘤学、姑息治疗与低收入或中等收入国家：行动呼吁
Glob Pediatr Health. 2023 Jul 21;10:2333794X231188591. doi: 10.1177/2333794X231188591. eCollection 2023.
2
Combination strategies to durably suppress HIV-1: Soluble T cell receptors.持久抑制HIV-1的联合策略：可溶性T细胞受体
J Virus Erad. 2022 Aug 24;8(3):100082. doi: 10.1016/j.jve.2022.100082. eCollection 2022 Sep.
3
So Pathogenic or So What?-A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research.如此致病还是怎样？——重点介绍 SIV 发病机制的简要概述及治愈研究
Viruses. 2022 Jan 12;14(1):135. doi: 10.3390/v14010135.
4
An overview on tumor treating fields (TTFields) technology as a new potential subsidiary biophysical treatment for COVID-19.肿瘤治疗电场（TTFields）技术概述——一种 COVID-19 治疗的潜在新型辅助生物物理治疗方法。
Drug Deliv Transl Res. 2022 Jul;12(7):1605-1615. doi: 10.1007/s13346-021-01067-5. Epub 2021 Sep 20.
5
Altruism: Scoping review of the literature and future directions for HIV cure-related research.利他主义：文献综述及艾滋病治愈相关研究的未来方向
J Virus Erad. 2020 Aug 25;6(4):100008. doi: 10.1016/j.jve.2020.100008. eCollection 2020 Nov.
本文引用的文献
1
BCL-2 antagonism sensitizes cytotoxic T cell-resistant HIV reservoirs to elimination ex vivo.BCL-2 拮抗作用使细胞毒性 T 细胞耐药的 HIV 储库易于体外清除。
J Clin Invest. 2020 May 1;130(5):2542-2559. doi: 10.1172/JCI132374.
2
Robust and persistent reactivation of SIV and HIV by N-803 and depletion of CD8 cells.N-803 诱导的 SIV 和 HIV 持久而稳健的再激活和 CD8 细胞耗竭。
Nature. 2020 Feb;578(7793):154-159. doi: 10.1038/s41586-020-1946-0. Epub 2020 Jan 22.
3
PD-1 Blockade and TLR7 Activation Lack Therapeutic Benefit in Chronic Simian Immunodeficiency Virus-Infected Macaques on Antiretroviral Therapy.抗 PD-1 治疗和 TLR7 激动剂治疗对慢性感染 SIV 的接受抗逆转录病毒治疗的猕猴无效。
Antimicrob Agents Chemother. 2019 Oct 22;63(11). doi: 10.1128/AAC.01163-19. Print 2019 Nov.
4
Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy.骨髓中前肿瘤性丙种球蛋白病中的干细胞样/固有 T 细胞、先天和髓样细胞的早期改变。
JCI Insight. 2019 Apr 23;5(11):127807. doi: 10.1172/jci.insight.127807.
5
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis.粪便微生物群移植治疗难治性免疫检查点抑制剂相关性结肠炎。
Nat Med. 2018 Dec;24(12):1804-1808. doi: 10.1038/s41591-018-0238-9. Epub 2018 Nov 12.
6
Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound.早期抗逆转录病毒疗法可限制 SIV 储存库的建立，从而延迟或预防治疗后病毒反弹。
Nat Med. 2018 Sep;24(9):1430-1440. doi: 10.1038/s41591-018-0130-7. Epub 2018 Aug 6.
7
Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection.急性 HIV 感染 Fiebig I 期患者中，经抗逆转录病毒治疗中断后 HIV RNA 迅速反弹。
Nat Med. 2018 Jul;24(7):923-926. doi: 10.1038/s41591-018-0026-6. Epub 2018 Jun 11.
8
Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency.程序性细胞死亡蛋白-1 有助于 HIV-1 潜伏的建立和维持。
AIDS. 2018 Jul 17;32(11):1491-1497. doi: 10.1097/QAD.0000000000001849.
9
Simian Immunodeficiency Virus (SIV)-Specific Chimeric Antigen Receptor-T Cells Engineered to Target B Cell Follicles and Suppress SIV Replication.靶向 B 细胞滤泡并抑制 SIV 复制的 SIV 特异性嵌合抗原受体 T 细胞。
Front Immunol. 2018 Mar 20;9:492. doi: 10.3389/fimmu.2018.00492. eCollection 2018.
10
Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal .白细胞介素 15 刺激的自然杀伤细胞在潜伏期逆转后清除 HIV-1 感染的细胞。
J Virol. 2018 May 29;92(12). doi: 10.1128/JVI.00235-18. Print 2018 Jun 15.
Zotero 插件